CA2869602A1 - Substituted pyrazole compounds as lpar antagonists - Google Patents

Substituted pyrazole compounds as lpar antagonists Download PDF

Info

Publication number
CA2869602A1
CA2869602A1 CA2869602A CA2869602A CA2869602A1 CA 2869602 A1 CA2869602 A1 CA 2869602A1 CA 2869602 A CA2869602 A CA 2869602A CA 2869602 A CA2869602 A CA 2869602A CA 2869602 A1 CA2869602 A1 CA 2869602A1
Authority
CA
Canada
Prior art keywords
phenyl
pyrazol
methyl
acid
biphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2869602A
Other languages
English (en)
French (fr)
Inventor
Stephen Deems Gabriel
Matthew Michael Hamilton
Yimin Qian
Achyutharao Sidduri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48656033&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2869602(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CA2869602A1 publication Critical patent/CA2869602A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA2869602A 2012-06-20 2013-06-17 Substituted pyrazole compounds as lpar antagonists Abandoned CA2869602A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261661958P 2012-06-20 2012-06-20
US61/661,958 2012-06-20
PCT/EP2013/062458 WO2013189862A1 (en) 2012-06-20 2013-06-17 Substituted pyrazole compounds as lpar antagonists

Publications (1)

Publication Number Publication Date
CA2869602A1 true CA2869602A1 (en) 2013-12-27

Family

ID=48656033

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2869602A Abandoned CA2869602A1 (en) 2012-06-20 2013-06-17 Substituted pyrazole compounds as lpar antagonists

Country Status (22)

Country Link
US (1) US20150259295A1 (instruction)
EP (1) EP2864294A1 (instruction)
JP (1) JP2015520201A (instruction)
KR (1) KR20150011003A (instruction)
CN (1) CN104411690A (instruction)
AU (1) AU2013279510A1 (instruction)
BR (1) BR112014031108A2 (instruction)
CA (1) CA2869602A1 (instruction)
CL (1) CL2014003242A1 (instruction)
CO (1) CO7160077A2 (instruction)
CR (1) CR20140516A (instruction)
EA (1) EA201492283A1 (instruction)
HK (1) HK1206341A1 (instruction)
IL (1) IL236091A0 (instruction)
IN (1) IN2014DN09347A (instruction)
MA (1) MA37765A1 (instruction)
MX (1) MX2014014105A (instruction)
PE (1) PE20142445A1 (instruction)
PH (1) PH12014502364A1 (instruction)
SG (1) SG11201407229UA (instruction)
UA (1) UA109867C2 (instruction)
WO (1) WO2013189862A1 (instruction)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2744807A4 (en) 2011-08-15 2015-03-04 Intermune Inc COMPOUNDS AS LYSOPHOSPHIC ACID RECEPTOR ANTAGONISTS
MX382748B (es) 2013-03-15 2025-03-13 Epigen Biosciences Inc Compuestos heterociclicos utiles para el tratamiento de una enfermedad.
RU2689315C2 (ru) 2014-06-27 2019-05-27 Убе Индастриз, Лтд. Соль гетероциклического соединения, замещенного галогеном
CN111699180B (zh) * 2017-12-19 2024-11-29 百时美施贵宝公司 作为lpa拮抗剂的吡唑n-连接的氨基甲酰基环己基酸
CN111434655A (zh) * 2019-01-15 2020-07-21 武汉朗来科技发展有限公司 溶血磷脂酸受体拮抗剂及其制备方法
JP7431961B2 (ja) 2019-11-15 2024-02-15 ギリアード サイエンシーズ， インコーポレイテッド Ｌｐａ受容体アンタゴニストとしてのトリアゾールカルバメートピリジルスルホンアミド及びその使用
CN115867556B (zh) 2020-06-03 2025-05-06 吉利德科学公司 Lpa受体拮抗剂及其用途
TWI838626B (zh) 2020-06-03 2024-04-11 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
KR20240005892A (ko) 2021-05-11 2024-01-12 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제 및 이의 용도
KR20240115978A (ko) 2021-12-08 2024-07-26 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제 및 이의 용도

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005063241A1 (ja) * 2003-12-26 2005-07-14 Ono Pharmaceutical Co., Ltd. ミトコンドリアベンゾジアゼピン受容体介在性疾患の予防および／または治療剤
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
GB2466121B (en) * 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2470833B (en) * 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
JP2013501064A (ja) * 2009-08-04 2013-01-10 アミラ ファーマシューティカルス，インコーポレーテッド リゾホスファチジン酸受容体アンタゴニストとしての化合物
BR112013014019A2 (pt) * 2010-12-07 2016-09-13 Amira Pharmaceuticals Inc antagonistas do receptor do ácido lisofosfatídico e seus usos
WO2012138648A1 (en) * 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
EP2744807A4 (en) * 2011-08-15 2015-03-04 Intermune Inc COMPOUNDS AS LYSOPHOSPHIC ACID RECEPTOR ANTAGONISTS

Also Published As

Publication number Publication date
US20150259295A1 (en) 2015-09-17
PH12014502364A1 (en) 2015-01-12
KR20150011003A (ko) 2015-01-29
MX2014014105A (es) 2015-03-05
AU2013279510A1 (en) 2014-10-16
IL236091A0 (en) 2015-02-01
CL2014003242A1 (es) 2015-03-20
CO7160077A2 (es) 2015-01-15
EP2864294A1 (en) 2015-04-29
CN104411690A (zh) 2015-03-11
HK1206341A1 (en) 2016-01-08
WO2013189862A1 (en) 2013-12-27
MA37765A1 (fr) 2017-04-28
JP2015520201A (ja) 2015-07-16
BR112014031108A2 (pt) 2017-06-27
SG11201407229UA (en) 2014-12-30
EA201492283A1 (ru) 2015-04-30
UA109867C2 (ru) 2015-10-12
CR20140516A (es) 2014-12-01
PE20142445A1 (es) 2015-01-28
IN2014DN09347A (instruction) 2015-07-17

Similar Documents

Publication Publication Date Title
CA2869602A1 (en) Substituted pyrazole compounds as lpar antagonists
US9321738B2 (en) N-alkyltriazole compounds as LPAR antagonists
EP2418202B1 (en) (4-[4-[5-(substituted amino)-pyridin-2-yl]phenyl]-cyclohexyl)-acetic acid derivatives as DGAT inhibitors
WO2013189865A1 (en) N-aryltriazole compounds as lpar antagonists
JP6854386B2 (ja) リゾホスファチジン酸受容体１（ｌｐａｒ１）阻害剤化合物
US9688642B2 (en) Substituted pyrazines as GPR40 agonists
EP3914256B1 (en) Gpr35 modulators
US7790754B2 (en) Alpha-hydroxy amides as bradykinin antagonists or inverse agonists
CA2877184A1 (en) Lpar-substituted cyanopyrazole compounds
JP2007501790A (ja) スルホニル置換ｎ−（ビアリールメチル）アミノシクロプロパンカルボキサミド
EP1893579B1 (en) 1-hydroxycycloalkanecarboxamide derivatives as bradykinin antagonists
KR102863894B1 (ko) Gpr35 조절제
HK40008389B (en) 1 h-pyrazol-1 -yl-thiazoles as inhibitors of lactate dehydrogenase and methods of use thereof
HK1162516B (en) (4-[4-[5-(substituted amino)-pyridin-2-yl]phenyl]-cyclohexyl)-acetic acid derivatives as dgat inhibitors

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20141003

FZDE Discontinued

Effective date: 20170529